- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-DYKDDDDK Tag magnetic beads
- Anti-DYKDDDDK Tag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Since Jan 2010, Selleck products have been cited in studies from top scientific journals.
16 Nobel Prize winners have published 52 articles with Selleck products.
David Baker
Won the Nobel Prize in Chemistry in 2024
Michael Houghton
Won the Nobel Prize in Physiology or Medicine in 2020
Charles M. Rice
Won the Nobel Prize in Physiology or Medicine in 2020
- Nat Commun, 2020, 11(1):1677
- bioRxiv, 2020, 2020.10.09.334128
- bioRxiv, 2020, 2020.01.20.910927
- Viruses, 2019, 11(11)E1039
- Cell Rep, 2018, 25(4):833-840.e3
- Cell, 2018, 172(3):423-438.e25
- Gastroenterology, 2017, 153(2):566-578.e5
- Gastroenterology, 2016, 150(1):82-85.e4
- Antimicrob, 2016, 60(6):3786-93
- Nature, 2015, 524(7566):471-5
- Antimicrob, 2015, 59(6):3482-92
- J Virol, 2014, 88(20):12098-111
- Antimicrob, 2014, 58(9):5386-94
- J Virol, 2013, 87(13):7593-607
- Nature, 2013, 501(7466):237-41
- Nature, 2013, 99(1):6-11
- Antimicrob, 2012, 56(10):5365-73
William G. Kaelin Jr
Won the Nobel Prize in Physiology or Medicine in 2019
Peter J. Ratcliffe
Won the Nobel Prize in Physiology or Medicine in 2019
Gregg L. Semenza
Won the Nobel Prize in Physiology or Medicine in 2019
Michael Rosbash
Won the Nobel Prize in Physiology or Medicine in 2017
Shinya Yamanaka
Won the Nobel Prize in Physiology or Medicine in 2012
Eric Richard Kandel
Won the Nobel Prize in Physiology or Medicine in 2000
Aziz Sancar
Won the Nobel Prize in Chemistry in 2015
Brian K. Kobilka
Won the Nobel Prize in Chemistry in 2012
Robert Lefkowitz
Won the Nobel Prize in Chemistry in 2012
Featured Products
MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.
BI-2865 is a none-covalent pan-KRAS Inhibitor. It binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively and inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 ce
AZD0095 is a selective and orally active Monocarboxylate transporter 4 (MCT4) inhibitor with IC50 of 1.3 nM and effectively inhibits the tumor growth in NCI-H358 xenografts in combination with Cediranib.
RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).
HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells.
SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.
SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.
IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.
LDN-193189 (DM3189) 2HCl is a selective BMP signaling inhibitor, inhibits the ALK1, ALK2, ALK3 and ALK6 with IC50s of 0.8 nM, 0.8 nM, 5.3 nM and 16.7 nM in the kinase assay, respectively. LDN-193189 inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.
GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.
A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are unstable and should be fresh-prepared.
GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.
A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.
AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases.
PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.
STM2457 is a highly potent and selective first-in-class catalytic inhibitor of RNA Methyltransferase METTL3 with an IC50 of 16.9 nM. STM2457 is highly specific for METTL3 and showed no inhibition of other RNA methyltransferases.
Compound Libraries
A unique collection of 3193 approved drugs and API included in pharmacopoeia for high throughput screening (HTS) and high content screening (HCS).
FDA-approved & Passed Phase I Drug Library
A unique collection of 4210 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS).
Preclinical/Clinical Compound Library
A unique collection of 3603 preclinical and clinical compounds for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 10525 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 5309 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 2010 kinase inhibitors for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 3009 chemical compounds featured different core structures and structural diversities respectively for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 3673 natural products for high throughput screening (HTS) and high content screening (HCS).
Human Endogenous Metabolite Compound Library
840 small collections of human endogenous metabolites, involving multiple metabolic pathways, which can be used for high-throughput screening, opening up new ways for humans to treat various diseases such as tumors.
A unique collection of 433 alkaloid compounds used for high throughput screening(HTS) and high content screening(HCS).
New Products
Setidegrasib (KRAS G12D inhibitor 17, ASP3082) is a PROTAC-based KRAS degrader (DC50 = 37 nM) that specifically targets G12D-mutated KRAS protein for degradation. It demonstrates potent inhibition of p-ERK, p-AKT, and p-S6 signaling pathways in AsPC-1 cells. The compound shows significant antitumor efficacy across multiple murine xenograft models. Setidegrasib serves as a research tool for investigating KRAS(G12D)-driven solid tumors. (Blue: VHL ligand ; Black: linker ; Pink: G12D-targeting moiety ).
BBI-2779 is a potent, selective, and orally active inhibitor of CHK1 with an IC50 of 0.3 nM. It preferentially kills cancer cells containing extrachromosomal DNA (ecDNA) by inducing replication stress and cell death. In gastric cancer models with FGFR2 gene amplification on ecDNA, BBI-2779 suppresses tumor growth and prevents drug resistance.
Chiglitazar (Carfloglitazar) is a potent dual agonist of PPARα and PPARγ with EC50 values of 1.2 μM and 0.08 μM, respectively, and also activates PPARδ with an EC50 of 1.7 μM. It effectively improves insulin resistance and corrects dyslipidemia in monosodium L-glutamate (MSG)-induced obese rats.
Acivicin hydrochloride (AT-125 hydrochloride) is the hydrochloride salt of Acivicin, a natural antibiotic produced by Streptomyces sviceus. It is a potent inhibitor of γ-glutamyl transpeptidase (GGT), an enzyme that initiates glutathione catabolism to cysteine. Acivicin also exhibits anti-cancer and anti-parasitic properties.
20-HETE (20-Hydroxyeicosatetraenoic acid) is a cytochrome P450-derived metabolite of arachidonic acid that plays a dual role in blood pressure regulation. It lowers blood pressure by inhibiting sodium reabsorption and promoting natriuresis in the kidneys, but also raises blood pressure by sensitizing vascular smooth muscle to constrictors, increasing myogenic tone, and inducing endothelial dysfunction. Additionally, 20-HETE stimulates endothelial angiotensin-converting enzyme (ACE), activating a prohypertensive renin-angiotensin-aldosterone system (RAAS) feedback loop that contributes to hypertension and vascular remodeling.
BAY-850 is a potent and isoform-selective inhibitor of the ATPase family AAA domain-containing protein 2 (ATAD2) bromodomain, with an IC50 of 166 nM in TR-FRET assays. It induces ATAD2 bromodomain dimerization and effectively blocks its interaction with acetylated histones in vitro.
AZD5904 is a selective and irreversible human Myeloperoxidase (MPO) inhibitor. AZD5904 reduces 3-chlorotyrosine-modified MYBPC3 levels, restores MYBPC3 phosphorylation, and alleviates the calcium signalling and relaxation defects.
Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. Moracin O demonstrates potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1) with an IC50 value of 6.76 nM in a cell-based HRE assay. Moracin O attenuates reactive oxygen species (ROS) generation triggered by oxygen-glucose deprivation (OGD). Moracin O also exhibits neuroprotective and anti-inflammatory effects.
C12FDG (5-Dodecanoylaminofluorescein di-β-D-galactopyranoside) is a lipophilic green fluorescent probe used to detect β-galactosidase activity. C12FDG demonstrates greater sensitivity for measuring β-galactosidase activity in animal cells than fluorescein di(β-D-galactopyranoside).
BMS-986408 is a first-in-class dual inhibitor of DGKα and DGKζ, exhibiting IC₅₀ values of 0.0003 μM and 0.002 μM for DGKα and DGKζ lipid kinase activity, respectively. It potentiates T cell–receptor signaling and T-cell activation, enhancing the effectiveness of both PD-1 and CAR T-cell therapy in preclinical models.
3FAx-Neu5Ac is a fluorinated sialic acid analogue and an inhibitor of Sialyltransferase. It inhibited sialylation, leading to reduced MHC expression and suppression of myoblast fusion, suggesting that modulation of sialylation can be applied to regulate skeletal muscle cell differentiation.
USP5-IN-1 (compound 64) is a selective competitive inhibitor of USP5 zinc finger ubiquitin binding domain (ZnF-UBD) with a Kd of 2.8 μM. It competitively blocks ubiquitin binding to the ZnF-UBD domain, suppressing USP5 catalytic activity and ubiquitin chain hydrolysis, with potential applications as a chemical probe and therapeutic agent in USP5-related cancers.
FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS).
GPX4-IN-5 is a potent covalent inhibitor of GPX4 with IC50 value of 0.12 μM. It induces ferroptosis and exhibits potent anti-tumor activity, making it a promising compound for triple-negative breast cancer (TNBC) research.
Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy.
Gly-β-MCA is a bile acid derivative that functions as a stable, orally active, and intestine-specific farnesoid X receptor (FXR) antagonist with potential therapeutic applications in metabolic diseases.
CSN5i-3 is a selective, orally bioavailable CSN5/Jab1 inhibitor that demonstrates potent activity in suppressing CSN-mediated Cul1 deneddylation, exhibiting an IC50 of 5.8 nM.
T6167923 is a selective MyD88-dependent signaling pathway inhibitor that directly interacts with the Toll/IL-1 receptor (TIR) domain of MyD88, preventing its homodimerization. This compound demonstrates inhibitory effects on NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity and exhibits anti-inflammatory properties, with IC50 values of 2.7 μM (IFN-γ), 2.9 μM (IL-1β), 2.66 μM (IL-6), and 2.66 μM (TNF-α).
FM4-64 is a highly lipophilic yet water-soluble styryl dye that specifically binds to cellular membranes and intracellular organelles, generating fluorescence. This compound serves as a valuable marker for studying endocytic and exocytic membrane structures.
GLPG0974 is a potent antagonist of free fatty acid receptor-2 (FFA2/GPR43), exhibiting an IC50 value of 9 nM.
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.